SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Crowdfunding concept with money icon and human hands in retro 80s collage mixed media vector illustration. Idea for financing business project, funding, philanthropy, cooperation, bank credit and startup development.
Manufacturing
BMS-Partnered Cellares Raises $257M for Cell Therapy Manufacturing Expansion
Cellares, which last year became the first company to receive the FDA’s new advanced manufacturing technology designation, expects to support clinical production this year and offer commercial-scale manufacturing services in 2027.
January 28, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: J&J's office in Madrid, Spain
Cancer
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed patients with multiple myeloma, regardless of eligibility for stem cell transplantation.
January 28, 2026
 · 
2 min read
 · 
Tristan Manalac
Sunset skyline of San Diego downtown viewed from Coronado Island.
gene therapy
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just as regulatory and government policies spark momentum and frustration.
January 28, 2026
 · 
4 min read
 · 
Heather McKenzie
Image picture pin up collage poster of falling man guy from destroyed arrow rise up bankrupt concept.
Cancer
Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data
Onvansertib cut the risk of death or disease progression by 62% versus standard of care, but analysts await more detailed data.
January 28, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
 · 
1 min read
 · 
Heather McKenzie
A contemporary art collage depicting a giant ear listening to a message bubble while covering it with a hand. The concept of taking in a useful experience or overhearing a new idea.
Gene editing
Lilly Leans Into Hearing Loss in $1.12B+ Gene Editing Pact With Seamless
The deal will help bolster Eli Lilly’s growing hearing loss portfolio, which is anchored by the gene therapy AK-OTOF.
January 28, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration showing two hands putting objects on scales
Career Advice
Subtraction Before Addition: A Smarter Way To Set and Execute Goals
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
January 28, 2026
 · 
6 min read
 · 
Angela Justice
Employer Resources
Report: 2026 Employment Outlook
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
January 28, 2026
 · 
1 min read
 · 
BioSpace Insights
The headquarters of Intellia Therapeutics, a brick building with two triangular shapes in its roof
Gene editing
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
January 27, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS